On November 15, 2019, Food and Drug Administration approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Read the full press release from the FDA here:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-...